A new partnership has been announced between CatSci Ltd, innovation partner for medicines development, and AGC Pharma Chemicals, a global small molecule Contract Development and Manufacturing Organisation (CDMO).
The deal will enable CatSci’s customers to harness AGC’s expertise in GMP manufacturing from kilos to tonnes to support clinical phase projects. AGC customers can leverage CatSci’s chemical development, analytical development, crystallisation and solid form, pre-formulation and high potency API capabilities alongside CMC expertise for the development of their new therapeutics.
The companies say the new streamlined tech transfer workflows will ensure a “seamless process knowledge and information transfer from development to manufacturing”.
AGC Pharma Chemicals have more than 40 years of small molecule CDMO and 60 years of API manufacturing experience, producing high-quality chemical compounds.
CatSci, based in Cardiff, develop economically and environmentally sustainable processes for drug development to address critical healthcare needs, including antimicrobial resistance, cancer, and mental health.
The new alliance aims to add strategic value to their customers’ drug development journey. The companies will work together to provide scalable small molecule API manufacturing, from grams to tonnes, supporting projects from pre-clinical development to large scale commercial production.
Customers will get access to a wide range of manufacturing technologies including fluorination, bromination, hydrogenation, cryogenic, HPAPI, micronisation and continuous flow to support their complex manufacturing programmes.
Dr Jerome Théobald, CatSci’s Chief Operating Officer, said: “I am thrilled that CatSci is partnering with AGC Pharma Chemicals; they are a leading small molecule CDMO with 40 years’ experience and CatSci are excited about what our partnership means for our customers. I am confident that AGC’s excellent cGMP manufacturing capabilities will add strategic value to our customers’ pipeline, accelerating their path to clinic.
“At CatSci, we are driven by our purpose to get new medicines into the hands of patients in need, and it was clear from the start that AGC Pharma Chemicals are aligned with us on this goal. Our partnership is built on our commitment to solve our customers’ challenges, allowing them to advance seamlessly through their pharmaceutical development from drug substance to drug product.”
Hiro Kadokura, AGC Pharma Chemicals Europe’s Chief Executive Officer, said: “It is great to have CatSci as a partner of AGC Pharma Chemicals, as we can provide seamless service to our customers from pre-clinical to the launch. Together with the strong cGMP CDMO capability of AGC Pharma Chemicals, and the excellent CRO capability of CatSci, we can cover especially early phase projects leveraging the effective expertise of each company. I am excited about this partnership that will bring great value to our customers.”